Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q3 2021 · 10-Q
Revenue$747.05M$747.05M+15.4% vs Q3 2020 Net Income$3.93B$3.93B+198.9% vs Q3 2020 EPS Diluted$130.02$130.02+197.9% vs Q3 2020 Gross Profit$436,500,000+18.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
Operating Cash Flowderived$230,363,000+69.8% Free Cash Flowderived$195,735,000+69.2% Margins · derivedGross margin58.4%+1.7 pt vs Q3 2020
Operating margin21.0%+4.1 pt vs Q3 2020
Net margin526.0%
ended Sep 30, 2021 · filed Oct 29, 2021 · 29 d after period end